Filing Flows › Celldex Therapeutics (CLDX) › Q2 2025
Celldex Therapeutics (CLDX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Celldex Therapeutics (CLDX) reported revenue of $730K for the second quarter 2025 (Q2 2025), -71% from a year earlier and +5% from the quarter before.
Celldex Therapeutics, Q2 2025: revenue $730K (-71% year over year), net loss $56.6M, operating cash flow −$44.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $730K | +5% | -71% |
| Operating profit | −$63.9M | — | — |
| Net earnings | −$56.6M | — | — |
| Operating cash flow | −$44.0M | — | — |
What changed
Revenue was $730K in Q2 2025, down 71% year over year and up 5% from the previous quarter. Contracts and grants was the largest line at 99% of revenue. Contracts and grants lost $1.8M year over year (down 71%), 100% of the total change.
Operating costs exceeded revenue by $63.9M, an operating margin of -8747.5%. Total costs grew 32% against a revenue fall of 71%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $56.6M, wider than the previous quarter's $53.8M loss.
Operating cash flow was −$44.0M. Non-cash charges added back $873K of depreciation and amortization and $9.2M of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $728K exceeded it, leaving free cash flow of −$44.7M.
Questions
What was Celldex Therapeutics' revenue in the second quarter 2025?
Celldex Therapeutics (CLDX) reported revenue of $730K for the second quarter 2025 (Q2 2025), -71% from a year earlier and +5% from the quarter before.